Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The human cytomegalovirus virion is a large enveloped DNA virus belonging to the Herpesviridae family. Its structure consists of an inner capsid containing double-stranded DNA surrounded by a protein-rich tegument layer and an outer lipid envelope studded with numerous viral glycoproteins. These antigenic components, collectively referred to as "cytomegalovirus antigens," include major targets like glycoprotein B (gB), which mediates membrane fusion during cell entry; other important envelope complexes such as gM/gN; several capsid proteins responsible for genome packaging; and various tegument proteins involved in assembly and modulation of host responses. The diversity among these molecules means that “cytomegalovirus virion/antigen” does not refer to one unique entity but rather encompasses all immunogenic structures present on the intact virus particle. This term "Cytomegalovirus virion/antigen" is not a specific molecular target but rather refers to the entire set of antigens present on or within the human cytomegalovirus (HCMV) virion. This includes multiple viral proteins from different structural regions (capsid, tegument, envelope), not a single defined molecule. For structured data, it is preferable to specify individual antigens such as "Glycoprotein B" or "Major capsid protein". These antigens elicit both humoral and cellular immune responses during natural infection or vaccination attempts. They play critical roles in pathogenesis—enabling cell entry, evading immunity—and serve as key biomarkers for diagnosis while being targets under investigation for vaccines or antibody-based therapies against HCMV infections.
Antiviral drugs inhibit DNA polymerase activity after phosphorylation by viral kinases. Monoclonal antibodies neutralize virus by binding to surface glycoproteins such as gB or gM/gN complexes, blocking attachment/fusion with host cells or marking for immune clearance.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human cytomegalovirus virion antigen (HCMV antigen).